201 related articles for article (PubMed ID: 22394984)
1. Pharmacokinetics and safety of bortezomib in patients with advanced malignancies and varying degrees of liver dysfunction: phase I NCI Organ Dysfunction Working Group Study NCI-6432.
LoRusso PM; Venkatakrishnan K; Ramanathan RK; Sarantopoulos J; Mulkerin D; Shibata SI; Hamilton A; Dowlati A; Mani S; Rudek MA; Takimoto CH; Neuwirth R; Esseltine DL; Ivy P
Clin Cancer Res; 2012 May; 18(10):2954-63. PubMed ID: 22394984
[TBL] [Abstract][Full Text] [Related]
2. Dose-escalating and pharmacological study of bortezomib in adult cancer patients with impaired renal function: a National Cancer Institute Organ Dysfunction Working Group Study.
Leal TB; Remick SC; Takimoto CH; Ramanathan RK; Davies A; Egorin MJ; Hamilton A; LoRusso PA; Shibata S; Lenz HJ; Mier J; Sarantopoulos J; Mani S; Wright JJ; Ivy SP; Neuwirth R; von Moltke L; Venkatakrishnan K; Mulkerin D
Cancer Chemother Pharmacol; 2011 Dec; 68(6):1439-47. PubMed ID: 21479634
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic, pharmacodynamic and covariate analysis of subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma.
Moreau P; Karamanesht II; Domnikova N; Kyselyova MY; Vilchevska KV; Doronin VA; Schmidt A; Hulin C; Leleu X; Esseltine DL; Venkatakrishnan K; Skee D; Feng H; Girgis S; Cakana A; van de Velde H; Deraedt W; Facon T
Clin Pharmacokinet; 2012 Dec; 51(12):823-9. PubMed ID: 23018466
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic and pharmacodynamic study of two doses of bortezomib in patients with relapsed multiple myeloma.
Reece DE; Sullivan D; Lonial S; Mohrbacher AF; Chatta G; Shustik C; Burris H; Venkatakrishnan K; Neuwirth R; Riordan WJ; Karol M; von Moltke LL; Acharya M; Zannikos P; Keith Stewart A
Cancer Chemother Pharmacol; 2011 Jan; 67(1):57-67. PubMed ID: 20306195
[TBL] [Abstract][Full Text] [Related]
5. Effect of the CYP3A inhibitor ketoconazole on the pharmacokinetics and pharmacodynamics of bortezomib in patients with advanced solid tumors: a prospective, multicenter, open-label, randomized, two-way crossover drug-drug interaction study.
Venkatakrishnan K; Rader M; Ramanathan RK; Ramalingam S; Chen E; Riordan W; Trepicchio W; Cooper M; Karol M; von Moltke L; Neuwirth R; Egorin M; Chatta G
Clin Ther; 2009; 31 Pt 2():2444-58. PubMed ID: 20110052
[TBL] [Abstract][Full Text] [Related]
6. Effect of cytochrome P450 3A4 inducers on the pharmacokinetic, pharmacodynamic and safety profiles of bortezomib in patients with multiple myeloma or non-Hodgkin's lymphoma.
Hellmann A; Rule S; Walewski J; Shpilberg O; Feng H; van de Velde H; Patel H; Skee DM; Girgis S; Louw VJ
Clin Pharmacokinet; 2011 Dec; 50(12):781-91. PubMed ID: 22087865
[TBL] [Abstract][Full Text] [Related]
7. Open-label study to evaluate trifluridine/tipiracil safety, tolerability and pharmacokinetics in patients with advanced solid tumours and hepatic impairment.
Saif MW; Rosen L; Rudek MA; Sun W; Shepard DR; Becerra C; Yamashita F; Bebeau P; Winkler R
Br J Clin Pharmacol; 2019 Jun; 85(6):1239-1246. PubMed ID: 30628113
[TBL] [Abstract][Full Text] [Related]
8. A phase I study of bortezomib and temozolomide in patients with advanced solid tumors.
Portnow J; Frankel P; Koehler S; Twardowski P; Shibata S; Martel C; Morgan R; Cristea M; Chow W; Lim D; Chung V; Reckamp K; Leong L; Synold TW
Cancer Chemother Pharmacol; 2012 Feb; 69(2):505-14. PubMed ID: 21850464
[TBL] [Abstract][Full Text] [Related]
9. Phase I and II pharmacokinetic and pharmacodynamic study of the proteasome inhibitor bortezomib in Japanese patients with relapsed or refractory multiple myeloma.
Ogawa Y; Tobinai K; Ogura M; Ando K; Tsuchiya T; Kobayashi Y; Watanabe T; Maruyama D; Morishima Y; Kagami Y; Taji H; Minami H; Itoh K; Nakata M; Hotta T
Cancer Sci; 2008 Jan; 99(1):140-4. PubMed ID: 17970782
[TBL] [Abstract][Full Text] [Related]
10. Effect of the cytochrome P450 2C19 inhibitor omeprazole on the pharmacokinetics and safety profile of bortezomib in patients with advanced solid tumours, non-Hodgkin's lymphoma or multiple myeloma.
Quinn DI; Nemunaitis J; Fuloria J; Britten CD; Gabrail N; Yee L; Acharya M; Chan K; Cohen N; Dudov A
Clin Pharmacokinet; 2009; 48(3):199-209. PubMed ID: 19385713
[TBL] [Abstract][Full Text] [Related]
11. A phase I and pharmacokinetic study of oxaliplatin and bortezomib: activity, but dose-limiting neurotoxicity.
Kobrinsky B; Joseph SO; Muggia F; Liebes L; Beric A; Malankar A; Ivy P; Hochster H
Cancer Chemother Pharmacol; 2013 Nov; 72(5):1073-8. PubMed ID: 24048674
[TBL] [Abstract][Full Text] [Related]
12. Phase I trial of bortezomib in combination with docetaxel in patients with advanced solid tumors.
Messersmith WA; Baker SD; Lassiter L; Sullivan RA; Dinh K; Almuete VI; Wright JJ; Donehower RC; Carducci MA; Armstrong DK
Clin Cancer Res; 2006 Feb; 12(4):1270-5. PubMed ID: 16489083
[TBL] [Abstract][Full Text] [Related]
13. Bortezomib in patients with renal impairment.
Kaygusuz I; Toptas T; Aydin F; Uzay A; Firatli-Tuglular T; Bayik M
Hematology; 2011 Jul; 16(4):200-8. PubMed ID: 21756535
[TBL] [Abstract][Full Text] [Related]
14. A phase I pharmacodynamic trial of bortezomib in combination with doxorubicin in patients with advanced cancer.
LoConte NK; Thomas JP; Alberti D; Heideman J; Binger K; Marnocha R; Utecht K; Geiger P; Eickhoff J; Wilding G; Kolesar J
Cancer Chemother Pharmacol; 2008 Dec; 63(1):109-15. PubMed ID: 18322686
[TBL] [Abstract][Full Text] [Related]
15. Prospective comparison of subcutaneous versus intravenous administration of bortezomib in patients with multiple myeloma.
Moreau P; Coiteux V; Hulin C; Leleu X; van de Velde H; Acharya M; Harousseau JL
Haematologica; 2008 Dec; 93(12):1908-11. PubMed ID: 18768528
[TBL] [Abstract][Full Text] [Related]
16. Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer.
Papandreou CN; Daliani DD; Nix D; Yang H; Madden T; Wang X; Pien CS; Millikan RE; Tu SM; Pagliaro L; Kim J; Adams J; Elliott P; Esseltine D; Petrusich A; Dieringer P; Perez C; Logothetis CJ
J Clin Oncol; 2004 Jun; 22(11):2108-21. PubMed ID: 15169797
[TBL] [Abstract][Full Text] [Related]
17. Phase I and Pharmacokinetic Study of Romidepsin in Patients with Cancer and Hepatic Dysfunction: A National Cancer Institute Organ Dysfunction Working Group Study.
Connolly RM; Laille E; Vaishampayan U; Chung V; Kelly K; Dowlati A; Alese OB; Harvey RD; Haluska P; Siu LL; Kummar S; Piekarz R; Ivy SP; Anders NM; Downs M; O'Connor A; Scardina A; Saunders J; Rosner GL; Carducci MA; Rudek MA;
Clin Cancer Res; 2020 Oct; 26(20):5329-5337. PubMed ID: 32816943
[TBL] [Abstract][Full Text] [Related]
18. A phase I, open-label, multicenter study to evaluate the pharmacokinetics and safety of oral panobinostat in patients with advanced solid tumors and various degrees of hepatic function.
Slingerland M; Hess D; Clive S; Sharma S; Sandstrom P; Loman N; Porro MG; Mu S; Waldron E; Valera SZ; Gelderblom H
Cancer Chemother Pharmacol; 2014 Nov; 74(5):1089-98. PubMed ID: 25253045
[TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy of targeted-dose busulfan and bortezomib as a conditioning regimen for patients with relapsed multiple myeloma undergoing a second autologous blood progenitor cell transplantation.
Freytes CO; Toro JJ; Yeh RF; Stadtmauer EA; Ratanatharathorn V; Akpek G; Sahovic E; Tricot GJ; Shaughnessy PJ; White DJ; Rodriguez TE; Solomon SR; Yu LH; Zhao C; Patil S; Armstrong E; Smith A; Elekes A; Kato K; Reece DE
Biol Blood Marrow Transplant; 2014 Dec; 20(12):1949-57. PubMed ID: 25139216
[TBL] [Abstract][Full Text] [Related]
20. Phase I study of pazopanib in patients with advanced solid tumors and hepatic dysfunction: a National Cancer Institute Organ Dysfunction Working Group study.
Shibata SI; Chung V; Synold TW; Longmate JA; Suttle AB; Ottesen LH; Lenz HJ; Kummar S; Harvey RD; Hamilton AL; O'Neil BH; Sarantopoulos J; LoRusso P; Rudek MA; Dowlati A; Mulkerin DL; Belani CP; Gandhi L; Lau SC; Ivy SP; Newman EM
Clin Cancer Res; 2013 Jul; 19(13):3631-9. PubMed ID: 23653147
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]